Stammdaten
Ionis Pharmaceuticals, Inc. entdeckt und entwickelt RNA-zielgerichtete Therapeutika in den Vereinigten Staaten. Das Unternehmen bietet SPINRAZA zur Behandlung der spinalen Muskelatrophie (SMA) bei pädiatrischen und erwachsenen Patienten an; TEGSEDI, eine Injektion zur Behandlung der Polyneuropathie der hereditären Transthyretin-vermittelten Amyloidose bei Erwachsenen; und WAYLIVRA, eine Behandlung für das familiäre Chylomikronämie-Syndrom und die familiäre partielle Lipodystrophie. Das Unternehmen entwickelt auch Arzneimittel für verschiedene Indikationen, die sich in Phase-3-Studien befinden, darunter Eplontersen als monatlich selbst verabreichte subkutane Injektion zur Behandlung aller Arten von TTR-Amyloidose; Olezarsen für Patienten mit schwerem Hypertriglyceridämie (SHTG); Donidalorsen für Patienten mit hereditärem Angioödem; ION363 für Patienten mit amyotropher Lateralsklerose; Pelacarsen für Patienten mit etablierter kardiovaskulärer Erkrankung und erhöhtem Lipoprotein(a); und Tofersen zur Hemmung der Superoxiddismutase-1-Produktion. Darüber hinaus entwickelt das Unternehmen Arzneimittel für Stoffwechselerkrankungen, Infektionskrankheiten, Nierenkrankheiten, Augenkrankheiten und Krebs. Es hat eine strategische Zusammenarbeit mit Biogen Inc.; und Kooperations- und Lizenzierungsvereinbarungen mit AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc. und Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. wurde 1989 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.
Unternehmen & Branche
| Name | IONIS PHARMACEUTICALS INC |
|---|---|
| Ticker | IONS |
| CIK | 0000874015 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 462222100 |
|---|---|
| ISIN | US4622221004 |
| Typ | Common Stock |
| Marktkapitalisierung | 8,96 Mrd. USD |
| Beta | 0,36 |
Sitz & Kontakt
| Sitz (Inkorporation) | CA |
|---|---|
| Geschäftsadresse | 2855 GAZELLE COURT, 92010 CARLSBAD, CA |
| Telefon | 7609319200 |
| EIN (IRS) | 33-0336973 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | ISIS PHARMACEUTICALS INC (bis 2015) |
Bewertung
| KBV (P/B) | 18,32 vs. 5,57 (2021) ▲ |
|---|---|
| KUV (P/S) | 9,50 vs. 5,30 (2021) ▲ |
| FCF-Rendite | -3,6 % vs. 0,4 % (2021) ▼ |
Qualität & Bilanz
| Bruttomarge | 98,3 % vs. 98,7 % (2021) ≈ |
|---|---|
| Operative Marge | -40,4 % vs. -3,7 % (2021) ▼ |
| Nettomarge | -40,4 % vs. -3,5 % (2021) ▼ |
| ROIC | -15,1 % vs. -3,6 % (2021) ▼ |
| Zinsdeckungsgrad | -22,1 vs. -3,2 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 5,57 | 9,37 | 18,88 | 9,38 | 26,41 | 18,24 | |
| KUV (P/S) | 5,30 | 9,13 | 9,27 | 7,83 | 13,69 | 8,47 | |
| FCF-Rendite | 0,4 % | -5,4 % | -4,5 % | -9,9 % | -2,5 % | -10,8 % | |
| Buyback-Rendite | 0,0 % | 0,0 % | – | – | – | – | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 98,7 % | 97,6 % | 98,8 % | 98,4 % | 98,3 % | 98,4 % | |
| Operative Marge | -3,7 % | -69,8 % | -44,9 % | -67,4 % | -40,4 % | -33,3 % | |
| Nettomarge | -3,5 % | -45,9 % | -46,5 % | -64,4 % | -40,4 % | -30,9 % | |
| ROIC | -3,6 % | -13,9 % | -20,3 % | -23,1 % | -15,1 % | -43,6 % | |
| Zinsdeckungsgrad | -3,2 | -50,5 | -27,9 | -28,0 | -22,1 | -19,2 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
IONS
IONIS PHARMACEUTICALS INC
Effektiv
Neutral
Handelsvolumen
Hoch
Insider
0,0
Keine Insider-Käufe
Institutionell
35,5
73 neu, 199 erhöht, -2175686K $ netto
Aktivist
10,5
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 74.48 | -27.0 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 75.98 | -28.4 % vs SMA200 | |
| SMA-Cross | Bärisch | 10 % | DEATH | vor 18 Tagen @ 74.31 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 70.51 | EMA50: 73.51 | |
| MACD-Histogramm | Bärisch | 10 % | -3.161 | Bearisch | |
| RSI(14) | Bullisch | 10 % | 23.9 | Überverkauft | |
| Stoch %K(14) | Bullisch | 5 % | 2.7 | Überverkauft | |
| ADX(14)+DI | Bärisch | 10 % | 33.8 | +DI: 17.2 / −DI: 53.1 | |
| Z-Score(60) | Bullisch | 5 % | -3.40 | Extrem überverkauft | |
| 52W-Position | Neutral | 5 % | 29.9 % | Hoch 86.50 / Tief 40.69 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 1.8 % | Upper 93.59 / Mid 73.63 / Lower 53.66 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0599 | R²=0.03 / annualisiert -20.3 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -15.000 | 85,46 | -1.281.930,00 | -122,3% | |
| 2026-07-07 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -5.536 | 83,58 | -462.693,34 | -44,1% | |
| 2026-07-07 | Kordasiewicz Holly B. | Officer, EVP, Chief Development Officer | Open Market Sale | -362 | 84,30 | -30.516,60 | -2,9% | |
| 2026-07-07 | Diaz Allene M. | Director | Open Market Sale | -10.111 | 85,42 | -863.637,13 | -82,4% | |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open Market Sale | -99 | 79,45 | -7.865,55 | -0,8% | |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open Market Sale | -11.419 | 79,04 | -902.550,91 | -86,1% | |
| 2026-06-26 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -50.000 | 80,59 | -4.029.500,00 | -384,4% | |
| 2026-06-26 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -26.000 | 81,05 | -2.107.196,00 | -201,0% | |
| 2026-06-26 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -3.069 | 80,00 | -245.520,00 | -23,4% | |
| 2026-06-26 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -5.635 | 80,16 | -451.698,78 | -43,1% | |
| 2026-06-25 | Swayze Eric | Officer, EVP Research | Open Market Sale | -10.602 | 79,18 | -839.491,80 | -80,1% | |
| 2026-06-25 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -21.072 | 78,49 | -1.653.941,28 | -157,8% | |
| 2026-06-24 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -14.565 | 78,41 | -1.142.082,43 | -109,0% | |
| 2026-06-15 | BERTHELSEN SPENCER R | Director | Open Market Sale | -8.000 | 73,49 | -587.920,00 | -56,1% | |
| 2026-06-12 | Kordasiewicz Holly B. | Officer, EVP, Chief Development Officer | Open Market Sale | -19.842 | 74,05 | -1.469.306,05 | -140,2% | |
| 2026-06-12 | Kordasiewicz Holly B. | Officer, EVP, Chief Development Officer | Open Market Sale | -41.004 | 73,09 | -2.997.121,77 | -285,9% | |
| 2026-06-01 | BERTHELSEN SPENCER R | Director | Open Market Sale | -8.000 | 75,67 | -605.360,00 | -57,8% | |
| 2026-05-14 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -3.220 | 78,68 | -253.347,35 | -24,2% | |
| 2026-05-13 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -1.316 | 78,01 | -102.665,11 | -9,8% | |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Open Market Sale | -59.508 | 74,90 | -4.457.292,02 | -425,2% | |
| 2026-05-04 | LOSCALZO JOSEPH | Director | Open Market Sale | -17.781 | 75,58 | -1.343.934,21 | -128,2% | |
| 2026-05-01 | KLEIN JOSEPH III | Director | Open Market Sale | -1.431 | 74,45 | -106.534,23 | -10,2% | |
| 2026-05-01 | KLEIN JOSEPH III | Director | Open Market Sale | -8.680 | 73,35 | -636.704,04 | -60,7% | |
| 2026-04-28 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -1.626 | 71,79 | -116.726,80 | -11,1% | |
| 2026-04-16 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -973 | 75,04 | -73.015,87 | -7,0% | |
| 2026-04-16 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -4.902 | 75,17 | -368.488,24 | -35,2% | |
| 2026-04-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -5.619 | 74,56 | -418.952,64 | -40,0% | |
| 2026-04-15 | PARSHALL B LYNNE | Director | Open Market Sale | -4.466 | 76,19 | -340.264,54 | -32,5% | |
| 2026-04-15 | PARSHALL B LYNNE | Director | Open Market Sale | -534 | 76,97 | -41.101,98 | -3,9% | |
| 2026-04-02 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -6.193 | 74,05 | -458.613,33 | -43,8% | |
| 2026-04-01 | KLEIN JOSEPH III | Director | Open Market Sale | -20.105 | 75,50 | -1.517.987,82 | -144,8% | |
| 2026-04-01 | KLEIN JOSEPH III | Director | Open Market Sale | -2.216 | 75,95 | -168.314,06 | -16,1% | |
| 2026-03-19 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -5.812 | 70,97 | -412.486,36 | -39,4% | |
| 2026-03-17 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -10.172 | 73,21 | -744.661,60 | -71,0% | |
| 2026-03-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -205.608 | 72,38 | -14.882.112,65 | -1419,8% | |
| 2026-03-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -9.440 | 72,77 | -686.901,60 | -65,5% | |
| 2026-03-10 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -17.591 | 76,34 | -1.342.909,25 | -128,1% | |
| 2026-03-10 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -21.191 | 75,50 | -1.599.962,88 | -152,6% | |
| 2026-03-10 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -16.086 | 76,30 | -1.227.361,80 | -117,1% | |
| 2026-03-10 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -16.512 | 75,47 | -1.246.234,94 | -118,9% | |
| 2026-03-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10.148 | 75,25 | -763.662,37 | -72,9% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -117.604 | 75,26 | -8.850.641,83 | -844,4% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -7.382 | 74,11 | -547.087,40 | -52,2% | |
| 2026-03-09 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -1.684 | 75,58 | -127.281,77 | -12,1% | |
| 2026-03-04 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -238 | 80,00 | -19.040,00 | -1,8% | |
| 2026-03-04 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -201 | 80,00 | -16.080,00 | -1,5% | |
| 2026-03-04 | LOSCALZO JOSEPH | Director | Open Market Sale | -200 | 80,00 | -16.000,00 | -1,5% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -1.005 | 80,80 | -81.203,00 | -7,7% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -4.096 | 79,36 | -325.058,56 | -31,0% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -2.088 | 80,41 | -167.891,70 | -16,0% | |
| 2026-03-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -36 | 81,01 | -2.916,36 | -0,3% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -71.600 | 79,10 | -5.663.488,40 | -540,3% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -12.687 | 79,88 | -1.013.409,65 | -96,7% | |
| 2026-03-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -802 | 80,76 | -64.771,12 | -6,2% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -13.526 | 79,17 | -1.070.907,52 | -102,2% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -1.012 | 80,82 | -81.787,82 | -7,8% | |
| 2026-03-03 | KLEIN JOSEPH III | Director | Open Market Sale | -6.794 | 80,00 | -543.486,03 | -51,9% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -14.321 | 79,12 | -1.133.005,92 | -108,1% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -5.030 | 80,00 | -402.394,97 | -38,4% | |
| 2026-03-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -755 | 80,84 | -61.031,94 | -5,8% | |
| 2026-03-03 | LOSCALZO JOSEPH | Director | Open Market Sale | -832 | 80,33 | -66.832,81 | -6,4% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -39.265 | 79,11 | -3.106.411,21 | -296,4% | |
| 2026-03-03 | Diaz Allene M. | Director | Open Market Sale | -14.608 | 79,88 | -1.166.814,00 | -111,3% | |
| 2026-02-13 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6.207 | 82,07 | -509.402,90 | -48,6% | |
| 2026-02-13 | Swayze Eric | Officer, EVP Research | Open Market Sale | -9.435 | 81,56 | -769.511,05 | -73,4% | |
| 2026-02-11 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 82,72 | -413.588,50 | -39,5% | |
| 2026-02-06 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -29.430 | 85,79 | -2.524.820,30 | -240,9% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -20.000 | 82,60 | -1.651.980,00 | -157,6% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -48.626 | 83,03 | -4.037.338,98 | -385,2% | |
| 2026-02-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -16.463 | 83,03 | -1.366.896,55 | -130,4% | |
| 2026-01-30 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6.179 | 82,93 | -512.446,10 | -48,9% | |
| 2026-01-30 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -6.988 | 83,24 | -581.702,08 | -55,5% | |
| 2026-01-30 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -62.970 | 82,72 | -5.208.979,15 | -497,0% | |
| 2026-01-30 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -6.179 | 83,45 | -515.629,52 | -49,2% | |
| 2026-01-30 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -5.296 | 82,96 | -439.364,10 | -41,9% | |
| 2026-01-30 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -6.179 | 83,03 | -513.047,93 | -48,9% | |
| 2026-01-30 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -5.885 | 82,95 | -488.140,74 | -46,6% | |
| 2026-01-30 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -6.179 | 83,53 | -516.153,50 | -49,2% | |
| 2026-01-22 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3.977 | 81,34 | -323.490,37 | -30,9% | |
| 2026-01-16 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -8.353 | 75,95 | -634.410,35 | -60,5% | |
| 2026-01-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -49 | 75,97 | -3.722,53 | -0,4% | |
| 2026-01-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -9.884 | 75,34 | -744.660,56 | -71,0% | |
| 2026-01-16 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -9.191 | 75,84 | -697.045,44 | -66,5% | |
| 2026-01-16 | Kordasiewicz Holly B. | Officer, EVP, Chief Development Officer | Open Market Sale | -4.141 | 75,66 | -313.308,06 | -29,9% | |
| 2026-01-16 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -8.977 | 75,15 | -674.621,55 | -64,4% | |
| 2026-01-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -1.149 | 75,78 | -87.071,22 | -8,3% | |
| 2026-01-16 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -6.907 | 75,75 | -523.205,25 | -49,9% | |
| 2026-01-16 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -12.922 | 75,22 | -971.992,84 | -92,7% | |
| 2026-01-16 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -8.480 | 75,11 | -636.932,80 | -60,8% | |
| 2026-01-16 | Jenne Kyle | Officer, EVP, Chf GL Pdt Str Ofcr | Open Market Sale | -1.823 | 75,96 | -138.475,08 | -13,2% | |
| 2026-01-16 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -9.302 | 75,59 | -703.138,18 | -67,1% | |
| 2026-01-16 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -44.034 | 74,82 | -3.294.623,88 | -314,3% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -2.101 | 85,36 | -179.341,36 | -17,1% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -25.545 | 85,36 | -2.180.521,20 | -208,0% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -9.264 | 84,62 | -783.919,68 | -74,8% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3.829 | 84,62 | -324.009,98 | -30,9% | |
| 2026-01-07 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3.460 | 84,62 | -292.785,20 | -27,9% | |
| 2026-01-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -5.125 | 78,57 | -402.671,25 | -38,4% | |
| 2026-01-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -18.338 | 79,27 | -1.453.653,26 | -138,7% | |
| 2025-12-01 | WENDER JOSEPH H | Director | Open Market Sale | -7.429 | 81,23 | -603.485,90 | -57,6% | |
| 2025-12-01 | WENDER JOSEPH H | Director | Open Market Sale | -20.571 | 80,67 | -1.659.361,77 | -158,3% | |
| 2025-11-25 | KLEIN JOSEPH III | Director | Open Market Sale | -4.000 | 80,00 | -320.000,00 | -30,5% | |
| 2025-11-25 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -16.777 | 80,91 | -1.357.442,17 | -129,5% | |
| 2025-11-19 | HERMAN JOAN E | Director | Open Market Sale | -32.000 | 72,13 | -2.308.240,00 | -220,2% | |
| 2025-11-19 | HERMAN JOAN E | Director | Open Market Sale | -12.000 | 72,13 | -865.590,00 | -82,6% | |
| 2025-11-06 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -8.000 | 76,17 | -609.379,20 | -58,1% | |
| 2025-11-06 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -14.738 | 76,10 | -1.121.520,53 | -107,0% | |
| 2025-11-06 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -18.300 | 75,42 | -1.380.204,30 | -131,7% | |
| 2025-11-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -801 | 75,01 | -60.083,01 | -5,7% | |
| 2025-11-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -800 | 75,01 | -60.008,00 | -5,7% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -775 | 75,05 | -58.166,85 | -5,5% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -905 | 75,05 | -67.923,87 | -6,5% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -775 | 75,05 | -58.166,85 | -5,5% | |
| 2025-11-03 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -905 | 75,05 | -67.923,87 | -6,5% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -20.000 | 75,11 | -1.502.166,00 | -143,3% | |
| 2025-10-31 | LOSCALZO JOSEPH | Director | Open Market Sale | -16.000 | 75,10 | -1.201.668,80 | -114,6% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -34.664 | 75,11 | -2.603.554,11 | -248,4% | |
| 2025-10-31 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -34.585 | 75,11 | -2.597.620,56 | -247,8% | |
| 2025-10-31 | WENDER JOSEPH H | Director | Open Market Sale | -11.200 | 75,16 | -841.776,32 | -80,3% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -8.341 | 73,16 | -610.227,56 | -58,2% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -5.975 | 73,85 | -441.253,75 | -42,1% | |
| 2025-10-30 | WENDER JOSEPH H | Director | Open Market Sale | -2.484 | 72,19 | -179.319,96 | -17,1% | |
| 2025-10-16 | Swayze Eric | Officer, EVP Research | Open Market Sale | -53 | 73,62 | -3.901,93 | -0,4% | |
| 2025-10-16 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -1.263 | 73,62 | -92.983,70 | -8,9% | |
| 2025-10-15 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -12.425 | 72,23 | -897.398,11 | -85,6% | |
| 2025-10-15 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 71,74 | -358.721,50 | -34,2% | |
| 2025-10-15 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -6.000 | 72,94 | -437.653,80 | -41,8% | |
| 2025-10-14 | Birchler Brian | Officer, EVP, Corp and Development Ops | Open Market Sale | -11.475 | 72,03 | -826.589,00 | -78,9% | |
| 2025-10-06 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -3.241 | 69,27 | -224.488,19 | -21,4% | |
| 2025-10-06 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -1.625 | 69,37 | -112.725,11 | -10,8% | |
| 2025-10-06 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -437 | 69,26 | -30.268,24 | -2,9% | |
| 2025-10-06 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10.200 | 69,89 | -712.849,44 | -68,0% | |
| 2025-10-06 | Swayze Eric | Officer, EVP Research | Open Market Sale | -6.849 | 69,02 | -472.717,98 | -45,1% | |
| 2025-10-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -30.203 | 67,69 | -2.044.416,91 | -195,0% | |
| 2025-10-02 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -15.000 | 68,01 | -1.020.210,00 | -97,3% | |
| 2025-10-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -34.461 | 67,69 | -2.332.637,52 | -222,5% | |
| 2025-10-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -12.972 | 66,23 | -859.082,37 | -82,0% | |
| 2025-10-01 | Swayze Eric | Officer, EVP Research | Open Market Sale | -14.142 | 66,09 | -934.661,75 | -89,2% | |
| 2025-10-01 | WENDER JOSEPH H | Director | Open Market Sale | -16.800 | 65,50 | -1.100.384,88 | -105,0% | |
| 2025-09-30 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -57.900 | 65,24 | -3.777.668,13 | -360,4% | |
| 2025-09-30 | HOUGEN ELIZABETH L | Officer, EVP, Finance & CFO | Open Market Sale | -49.800 | 65,26 | -3.249.733,86 | -310,0% | |
| 2025-09-30 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -14.827 | 64,68 | -958.976,26 | -91,5% | |
| 2025-09-29 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -10.473 | 64,54 | -675.945,22 | -64,5% | |
| 2025-09-12 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -1.700 | 64,58 | -109.787,19 | -10,5% | |
| 2025-09-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -1.000 | 64,56 | -64.555,30 | -6,2% | |
| 2025-09-09 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -11.950 | 62,16 | -742.838,29 | -70,9% | |
| 2025-09-09 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -20.000 | 64,56 | -1.291.106,00 | -123,2% | |
| 2025-09-05 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -6.000 | 59,60 | -357.580,80 | -34,1% | |
| 2025-09-05 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -250 | 62,00 | -15.500,00 | -1,5% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -16.615 | 59,12 | -982.262,19 | -93,7% | |
| 2025-09-03 | WENDER JOSEPH H | Director | Open Market Sale | -11.200 | 60,14 | -673.548,96 | -64,3% | |
| 2025-09-03 | KLEIN JOSEPH III | Director | Open Market Sale | -28.000 | 60,00 | -1.680.000,00 | -160,3% | |
| 2025-09-03 | KLEIN JOSEPH III | Director | Open Market Sale | -28.000 | 60,00 | -1.680.000,00 | -160,3% | |
| 2025-09-03 | Devers Shannon L. | Officer, EVP, Chief Human Resources Ofc | Open Market Sale | -3.162 | 61,02 | -192.942,71 | -18,4% | |
| 2025-09-03 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -12.455 | 60,46 | -753.039,26 | -71,8% | |
| 2025-09-03 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -7.203 | 61,42 | -442.381,61 | -42,2% | |
| 2025-09-03 | LOSCALZO JOSEPH | Director | Open Market Sale | -16.000 | 60,15 | -962.371,20 | -91,8% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -127.500 | 60,13 | -7.667.046,75 | -731,5% | |
| 2025-09-03 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -59.699 | 61,06 | -3.645.394,07 | -347,8% | |
| 2025-09-03 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -33.909 | 60,62 | -2.055.563,58 | -196,1% | |
| 2025-09-03 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -65.475 | 60,89 | -3.986.772,75 | -380,4% | |
| 2025-09-03 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -11.375 | 61,42 | -698.652,50 | -66,7% | |
| 2025-09-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -30.000 | 59,09 | -1.772.592,00 | -169,1% | |
| 2025-09-03 | Baroldi Joseph | Officer, EVP, Chief Business Officer | Open Market Sale | -2.800 | 62,01 | -173.628,28 | -16,6% | |
| 2025-09-03 | WENDER JOSEPH H | Director | Open Market Sale | -11.200 | 60,14 | -673.548,96 | -64,3% | |
| 2025-09-02 | O'NEIL PATRICK R. | Officer, EVP CLO & General Counsel | Open Market Sale | -13.050 | 54,51 | -711.418,14 | -67,9% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -5.600 | 57,53 | -322.174,16 | -30,7% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -11.200 | 55,04 | -616.432,32 | -58,8% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -5.600 | 57,53 | -322.174,16 | -30,7% | |
| 2025-09-02 | PARSHALL B LYNNE | Director | Open Market Sale | -10.750 | 50,42 | -542.015,00 | -51,7% | |
| 2025-09-02 | PARSHALL B LYNNE | Director | Open Market Sale | -9.250 | 51,49 | -476.282,50 | -45,4% | |
| 2025-09-02 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -10.000 | 50,37 | -503.671,00 | -48,1% | |
| 2025-09-02 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -5.000 | 49,14 | -245.700,00 | -23,4% | |
| 2025-09-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -1.130 | 53,68 | -60.661,68 | -5,8% | |
| 2025-09-02 | Swayze Eric | Officer, EVP Research | Open Market Sale | -10.000 | 49,22 | -492.200,00 | -47,0% | |
| 2025-09-02 | WENDER JOSEPH H | Director | Open Market Sale | -11.200 | 55,04 | -616.432,32 | -58,8% | |
| 2025-08-22 | Diaz Allene M. | Director | Open Market Sale | -1.427 | 42,53 | -60.687,17 | -5,8% | |
| 2025-08-18 | BENNETT C FRANK | Officer, EVP, Chief Scientific Officer | Open Market Sale | -10.000 | 43,98 | -439.776,00 | -42,0% | |
| 2025-08-06 | PARSHALL B LYNNE | Director | Open Market Sale | -4.600 | 41,87 | -192.595,10 | -18,4% | |
| 2025-08-06 | PARSHALL B LYNNE | Director | Open Market Sale | -400 | 42,63 | -17.051,00 | -1,6% | |
| 2025-08-05 | Geary Richard S | Officer, EVP, Chief Development Officer | Open Market Sale | -10.000 | 42,86 | -428.593,00 | -40,9% | |
| 2025-08-04 | Schneider Eugene | Officer, EVP, Chf Clinical Develop Ofcr | Open Market Sale | -9.549 | 42,80 | -408.701,02 | -39,0% | |
| 2025-07-30 | Monia Brett P | Director, Officer, Chief Executive Officer | Open Market Sale | -2.432 | 45,00 | -109.440,00 | -10,4% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| FMR LLC | 31.545.637 | 0 | 31.545.637 | 1.854.485.054 | Neu | +100,0% | |
| Capital World Investors | 21.186.369 | 0 | 21.186.369 | 1.590.884.448 | Neu | +100,0% | |
| BlackRock, Inc. | 29.632.476 | 0 | 29.632.476 | 813.030.461 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.118.330 | 0 | 7.118.330 | 534.515.400 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 20.254.816 | 0 | 20.254.816 | 500.969.231 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 5.857.629 | 0 | 5.857.629 | 439.849.362 | Neu | +100,0% | |
| STATE STREET CORP | 15.895.564 | 0 | 15.895.564 | 318.078.660 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.984.332 | 0 | 3.984.332 | 305.196.969 | Neu | +100,0% | |
| ROYAL BANK OF CANADA | 5.961.815 | 0 | 5.961.815 | 288.743.000 | Neu | +100,0% | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 61.979.669 | 0 | 61.979.669 | 239.267.205 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 59.306.134 | 0 | 59.306.134 | 185.693.698 | Neu | +100,0% | |
| Tweedy, Browne Co LLC | 2.275.625 | 0 | 2.275.625 | 170.876.681 | Neu | +100,0% | |
| Artisan Partners Limited Partnership | 2.058.308 | 0 | 2.058.308 | 154.558.340 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 2.047.727 | 0 | 2.047.727 | 153.763.820 | Neu | +100,0% | |
| Deep Track Capital, LP | 1.950.000 | 0 | 1.950.000 | 146.425.500 | Neu | +100,0% | |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1.854.033 | 0 | 1.854.033 | 139.219.338 | Neu | +100,0% | |
| Bellevue Group AG | 1.818.665 | 0 | 1.818.665 | 136.563.555 | Neu | +100,0% | |
| VOYA INVESTMENT MANAGEMENT LLC | 85.319.136 | 0 | 85.319.136 | 133.812.360 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 4.159.847 | 0 | 4.159.847 | 131.346.886 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1.663.803 | 0 | 1.663.803 | 124.935.144 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.583.266 | 0 | 1.583.266 | 118.887.444 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 1.575.023 | 0 | 1.575.023 | 118.268.500 | Neu | +100,0% | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.475.632 | 0 | 1.475.632 | 110.805.207 | Neu | +100,0% | |
| Pictet Asset Management Holding SA | 1.434.995 | 0 | 1.434.995 | 107.076.549 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.222.459 | 0 | 1.222.459 | 91.794.446 | Neu | +100,0% | |
| DLD Asset Management, LP | 55.000.000 | 0 | 55.000.000 | 83.118.750 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 1.051.506 | 0 | 1.051.506 | 78.957.586 | Neu | +100,0% | |
| MORGAN STANLEY | 1.120.509 | 0 | 1.120.509 | 77.222.309 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 4.042.533 | 0 | 4.042.533 | 72.896.170 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 874.089 | 0 | 874.089 | 65.635.343 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 868.179 | 0 | 868.179 | 65.191.562 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.820.598 | 0 | 1.820.598 | 64.596.663 | Neu | +100,0% | |
| Polar Capital Holdings Plc | 829.511 | 0 | 829.511 | 62.287.981 | Neu | +100,0% | |
| GROUPAMA ASSET MANAGMENT | 824.540 | 0 | 824.540 | 61.914.709 | Neu | +100,0% | |
| LMR Partners LLP | 37.366.400 | 0 | 37.366.400 | 61.192.600 | Neu | +100,0% | |
| UBS Group AG | 928.443 | 0 | 928.443 | 60.886.735 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 785.281 | 0 | 785.281 | 58.967.000 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 760.318 | 0 | 760.318 | 57.092.279 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 737.859 | 0 | 737.859 | 55.405.832 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 35.000.000 | 0 | 35.000.000 | 52.894.100 | Neu | +100,0% | |
| Squarepoint Ops LLC | 695.276 | 0 | 695.276 | 52.208.275 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 672.858 | 0 | 672.858 | 50.524.907 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 666.116 | 0 | 666.116 | 50.018.650 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 660.144 | 0 | 660.144 | 49.570.211 | Neu | +100,0% | |
| Nuveen, LLC | 648.496 | 0 | 648.496 | 48.695.565 | Neu | +100,0% | |
| Eversept Partners, LP | 632.100 | 0 | 632.100 | 47.464.389 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 7.141.460 | 0 | 7.141.460 | 46.079.592 | Neu | +100,0% | |
| EVENTIDE ASSET MANAGEMENT, LLC | 575.000 | 0 | 575.000 | 43.176.750 | Neu | +100,0% | |
| TD ASSET MANAGEMENT INC | 529.954 | 0 | 529.954 | 39.794.246 | Neu | +100,0% | |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 523.932 | 0 | 523.932 | 39.342.055 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1018 von typischerweise 8355 Fonds (12 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| DAVENPORT & Co LLC | 283.960 | 238.238 | +19,2% | 22.515.188 | 50,10 | 88 % | 17 Q |
| Swedbank AB | 95.666 | 32.253 | +196,6% | 7.585.357 | 16,88 | 100 % | 13 Q |
| Y-Intercept (Hong Kong) Ltd | 67.374 | 0 | +100,0% | 5.342.084 | 11,89 | 100 % | 5 Q |
| Assenagon Asset Management S.A. | 40.927 | 33.673 | +21,5% | 3.245.102 | 7,22 | 100 % | 14 Q |
| Westmount Partners, LLC | 12.961 | 12.961 | 0,0% | 1.027.678 | 2,29 | 100 % | 15 Q |
| Plancorp, LLC | 11.128 | 11.208 | -0,7% | 631.514 | 1,41 | 0 % | 17 Q |
| PSP Research LLC | 6.800 | 6.800 | 0,0% | 539.172 | 1,20 | 0 % | 3 Q |
| Significant Wealth Partners LLC | 6.613 | 6.664 | -0,8% | 524.345 | 1,17 | 0 % | 7 Q |
| TEMA ETFS LLC | 5.525 | 5.673 | -2,6% | 438.077 | 0,97 | 100 % | 7 Q |
| Moisand Fitzgerald Tamayo, LLC | 5.000 | 5.000 | 0,0% | 396.450 | 0,88 | 100 % | 6 Q |
| Wedmont Private Capital | 6.723 | 6.564 | +2,4% | 391.615 | 0,87 | 0 % | 5 Q |
| Prospera Financial Services Inc | 4.194 | 4.341 | -3,4% | 332.511 | 0,74 | 0 % | 10 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 5.394 | 4.125 | +30,8% | 314.201 | 0,70 | 0 % | 6 Q |
| Everhart Financial Group, Inc. | 3.503 | 3.470 | +1,0% | 277.791 | 0,62 | 0 % | 3 Q |
| Victrix Investment Advisors | 3.400 | 0 | +100,0% | 269.586 | 0,60 | 0 % | 2 Q |
| QRG CAPITAL MANAGEMENT, INC. | 3.079 | 3.094 | -0,5% | 244.134 | 0,54 | 100 % | 2 Q |
| B. Riley Wealth Advisors, Inc. | 2.897 | 2.945 | -1,6% | 233.760 | 0,52 | 100 % | 8 Q |
| GAMMA Investing LLC | 2.168 | 1.766 | +22,8% | 171.901 | 0,38 | 100 % | 11 Q |
| Versant Capital Management, Inc | 1.460 | 1.555 | -6,1% | 115.763 | 0,26 | 100 % | 17 Q |
| HARBOR INVESTMENT ADVISORY, LLC | 1.407 | 0 | +100,0% | 111.561 | 0,25 | 100 % | 1 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 36 | 1,0 | 45 |
| 31.03.2026 | ✓ | 504 | 711,9 | 13.443 |
| 31.12.2025 | ✓ | 511 | 1.172,6 | 14.406 |
| 30.09.2025 | ✓ | 452 | 1.392,7 | 11.579 |
| 30.06.2025 | ✓ | 385 | 1.270,7 | 7.072 |
| 31.03.2025 | ✓ | 365 | 1.394,4 | 5.707 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 7.118.330 | 534.515.400 |
| PERCEPTIVE ADVISORS LLC | 504.000 | 37.845.360 |
| Capital Research Global Investors | 323.015 | 24.255.196 |
| TimesSquare Capital Management, LLC | 275.674 | 20.700.361 |
| Jump Financial, LLC | 206.675 | 15.519.226 |
| CAPITAL FUND MANAGEMENT S.A. | 142.201 | 10.677.873 |
| BRAIDWELL LP | 130.862 | 9.826.428 |
| Integral Health Asset Management, LLC | 125.000 | 9.386.250 |
| SEB Asset Management AB | 114.334 | 8.585.329 |
| WINTON GROUP Ltd | 106.532 | 7.999.488 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 58.942.534 | 56.807.898 | +2661.2 % | 158.390.974 |
| DLD Asset Management, LP | 55.000.000 | 28.500.000 | +107.5 % | 83.118.750 |
| LMR Partners LLP | 37.315.000 | 10.000.000 | +36.6 % | 57.332.974 |
| BNP PARIBAS FINANCIAL MARKETS | 7.141.460 | 6.775.852 | +1853.3 % | 46.079.592 |
| JPMORGAN CHASE & CO | 7.680.567 | 4.264.775 | +124.9 % | 179.229.388 |
| Capital World Investors | 21.186.369 | 3.225.070 | +18.0 % | 1.590.884.448 |
| WELLS FARGO & COMPANY/MN | 5.171.853 | 2.711.808 | +110.2 % | 21.788.345 |
| LORD, ABBETT & CO. LLC | 7.067.000 | 2.601.000 | +58.2 % | 10.645 |
| GOLDMAN SACHS GROUP INC | 4.159.847 | 1.301.881 | +45.6 % | 131.346.886 |
| M&G Plc | 7.345.423 | 1.002.000 | +15.8 % | 12.151.535 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| DeepCurrents Investment Group LLC | 27.422 | -50.399.578 | -99.9 % | 2.059.118 |
| CSS LLC/IL | 79.093 | -48.141.907 | -99.8 % | 5.939.093 |
| TWO SIGMA INVESTMENTS, LP | 5.857.629 | -47.051.017 | -88.9 % | 439.849.362 |
| MILLENNIUM MANAGEMENT LLC | 1.051.506 | -36.241.756 | -97.2 % | 78.957.586 |
| D. E. Shaw & Co., Inc. | 429.599 | -25.403.204 | -98.3 % | 32.258.589 |
| BALYASNY ASSET MANAGEMENT L.P. | 35.000.000 | -22.620.577 | -39.3 % | 52.894.100 |
| STATE STREET CORP | 15.895.564 | -13.574.301 | -46.1 % | 318.078.660 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 21.710.000 | -13.340.000 | -38.1 % | 32.944.940 |
| BANK OF AMERICA CORP /DE/ | 1.820.598 | -13.333.981 | -88.0 % | 64.596.663 |
| VOYA INVESTMENT MANAGEMENT LLC | 85.319.136 | -10.639.624 | -11.1 % | 133.812.360 |
Zusätzlich aktuell von 233 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 3,70 % | 6.159.027 | -1,90 pp | |
| 14.05.2026 | Capital World Investors | Passiv (13G/A) | 12,80 % | 21.186.369 | +1,70 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,05 % | 8.344.732 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,43 pp | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 5,60 % | 9.108.019 | -2,70 pp | |
| 07.01.2026 | Capital World Investors | Passiv (13G/A) | 11,10 % | 17.961.299 | +3,80 pp | |
| 14.11.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 8,30 % | 13.157.114 | -1,70 pp | |
| 12.08.2025 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G/A) | 4,30 % | 6.879.873 | -1,46 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 5,70 % | 9.066.517 | Neu | |
| 13.02.2025 | Capital World Investors | Passiv (13G) | 7,30 % | 11.465.413 | Neu | |
| 07.02.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 10,00 % | 15.851.863 | +1,00 pp | |
| 08.01.2025 | The Vanguard Group | Passiv (13G/A) | 10,43 % | 16.472.539 | +0,53 pp | |
| 14.11.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 9,00 % | 14.168.116 | -0,20 pp | |
| 14.11.2024 | Biotech Invest N.V. (+1) | Passiv (13G/A) | 5,00 % | 7.850.000 | -1,00 pp | |
| 08.11.2024 | Wellington Management Company LLP | Passiv (13G) | 5,63 % | 8.874.604 | Neu | |
| 08.11.2024 | Wellington Investment Advisors Holdings LLP (+2) | Passiv (13G) | 5,76 % | 9.067.836 | +0,96 pp | |
| 14.02.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 9,20 % | 13.201.453 | +1,00 pp | |
| 13.02.2024 | Biotech Invest N.V. (+1) | Passiv (13G/A) | 6,00 % | 8.590.000 | Neu | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 9,90 % | 14.203.481 | -0,17 pp | |
| 26.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 6,30 % | 9.057.282 | -0,20 pp | |
| 09.06.2023 | The Vanguard Group | Passiv (13G/A) | 10,07 % | 14.414.917 | +0,53 pp | |
| 14.02.2023 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 8,20 % | 11.678.259 | Neu | |
| 14.02.2023 | Biotech Invest N.V. (+1) | Passiv (13G/A) | 6,80 % | 9.635.000 | +0,90 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 9,54 % | 13.546.694 | +1,04 pp | |
| 01.02.2023 | . BlackRock, Inc. | Passiv (13G/A) | 6,50 % | 9.182.911 | +0,50 pp | |
| 10.08.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 3,30 % | 4.808.770 | -6,80 pp | |
| 11.04.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 10,10 % | 14.350.460 | +1,30 pp | |
| 14.02.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 8,80 % | 12.490.280 | -0,50 pp | |
| 11.02.2022 | Biotech Invest (+1) | Passiv (13G/A) | 7,20 % | 10.232.973 | Neu | |
| 10.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,50 % | 12.007.076 | -0,26 pp | |
| 09.02.2022 | ARK Investment Management LLC | Passiv (13G) | 5,02 % | 7.083.256 | Neu | |
| 01.02.2022 | . BlackRock, Inc. | Passiv (13G) | 6,00 % | 8.539.282 | -1,00 pp |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 246.091.000 $ | -92.528.000 $ | -0,56 $ | 3.449.969.000 $ | 491.414.000 $ |
| 2026-01-31 | 10-K | 15.000.000 $ | – | – | – | – |
| 2025-12-31 | 10-K | 943.711.000 $ | -381.387.000 $ | -2,38 $ | 3.523.836.000 $ | 489.089.000 $ |
| 2025-09-30 | 10-Q | 156.719.000 $ | -128.606.000 $ | -0,80 $ | 3.033.091.000 $ | 617.967.000 $ |
| 2025-06-30 | 10-Q | 452.049.000 $ | 123.551.000 $ | 0,70 $ | 2.985.133.000 $ | 631.724.000 $ |
| 2025-03-31 | 10-Q | 131.612.000 $ | -146.938.000 $ | -0,93 $ | 2.812.948.000 $ | 475.726.000 $ |
| 2024-12-31 | 10-K | 705.138.000 $ | -453.897.000 $ | -3,04 $ | 3.003.675.000 $ | 588.351.000 $ |
| 2024-10-31 | 10-Q | 30.000.000 $ | – | – | – | – |
| 2024-09-30 | 10-Q | 133.814.000 $ | -140.480.000 $ | -0,95 $ | 3.081.099.000 $ | 662.468.000 $ |
| 2024-06-30 | 10-Q | 225.250.000 $ | -66.265.000 $ | -0,45 $ | 2.691.128.000 $ | 263.698.000 $ |
| 2024-03-31 | 10-Q | 119.497.000 $ | -142.803.000 $ | -0,98 $ | 2.763.928.000 $ | 296.515.000 $ |
| 2023-12-31 | 10-K | 787.647.000 $ | -366.286.000 $ | -2,56 $ | 2.990.072.000 $ | 386.686.000 $ |
| 2023-09-30 | 10-Q | 144.207.000 $ | -147.410.000 $ | -1,03 $ | 2.933.971.000 $ | 315.460.000 $ |
| 2023-06-30 | 10-Q | 188.411.000 $ | -85.290.000 $ | -0,60 $ | 2.971.131.000 $ | 428.301.000 $ |
| 2023-03-31 | 10-Q | 130.524.000 $ | -124.323.000 $ | -0,87 $ | 2.885.221.000 $ | 486.570.000 $ |
| 2022-12-31 | 10-K | 587.367.000 $ | -269.722.000 $ | -1,90 $ | 2.533.876.000 $ | 572.887.000 $ |
| 2022-09-30 | 10-Q | 159.767.000 $ | -46.992.000 $ | -0,33 $ | 2.421.971.000 $ | 594.361.000 $ |
| 2022-06-30 | 10-Q | 133.791.000 $ | -105.135.000 $ | -0,74 $ | 2.456.133.000 $ | 624.726.000 $ |
| 2022-03-31 | 10-Q | 141.919.000 $ | -65.165.000 $ | -0,46 $ | 2.519.092.000 $ | 709.574.000 $ |
| 2021-12-31 | 10-K | 810.456.000 $ | -28.597.000 $ | -0,20 $ | 2.611.690.000 $ | 771.737.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Research And Development Revenue | 507,9 Mio. | 412,1 Mio. | 479,1 Mio. | 284,0 Mio. | 468,1 Mio. | 22,2 % | +23,2% | |
| Collaborative Agreement Revenue | 465,8 Mio. | 332,6 Mio. | 352,7 Mio. | 207,2 Mio. | 468,1 Mio. | 20,4 % | +40,0% | |
| Commercial | 435,8 Mio. | 293,1 Mio. | 308,6 Mio. | 303,4 Mio. | 342,4 Mio. | 19,0 % | +48,7% | |
| Royalty | 285,5 Mio. | – | – | – | – | 12,5 % | Neu | |
| Spinraza Royalties | 212,3 Mio. | 216,1 Mio. | 240,4 Mio. | 242,3 Mio. | 267,8 Mio. | 9,3 % | -1,8% | |
| Product | 115,3 Mio. | 34,2 Mio. | 34,9 Mio. | 30,1 Mio. | 55,5 Mio. | 5,0 % | +237,3% | |
| Tryngolza Sales | 107,5 Mio. | – | – | – | – | 4,7 % | Neu | |
| Wainus Royalties | 49,1 Mio. | 20,2 Mio. | – | – | – | 2,1 % | +142,9% | |
| Wainua Joint Development Revenue | 42,1 Mio. | 79,4 Mio. | 126,4 Mio. | 76,8 Mio. | – | 1,8 % | -47,0% | |
| Other Commercial | 35,0 Mio. | 56,8 Mio. | 68,2 Mio. | 61,0 Mio. | 74,6 Mio. | 1,5 % | -38,4% | |
| Other Royalties | 24,2 Mio. | – | – | – | – | 1,1 % | Neu | |
| Dawnzera Sales | 7,8 Mio. | – | – | – | – | 0,3 % | Neu | |
| Other | – | 22,6 Mio. | – | – | – | – | – | |
| Licensing And Other Royalties | – | – | 33,3 Mio. | 31,0 Mio. | 19,1 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 29.04.2026 | 246,1 Mio. USD | -0,56 |
| Q3 2025 | 30.09.2025 | 29.10.2025 | 156,7 Mio. USD | -0,80 |
| Q2 2025 | 30.06.2025 | 30.07.2025 | 452,0 Mio. USD | 0,70 |
| Q1 2025 | 31.03.2025 | 30.04.2025 | 131,6 Mio. USD | -0,93 |
| Q3 2024 | 30.09.2024 | 06.11.2024 | 133,8 Mio. USD | -0,95 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | 225,3 Mio. USD | -0,45 |
| Q1 2024 | 31.03.2024 | 07.05.2024 | 119,5 Mio. USD | -0,98 |
| Q3 2023 | 30.09.2023 | 02.11.2023 | 144,2 Mio. USD | -1,03 |
| Q2 2023 | 30.06.2023 | 09.08.2023 | 188,4 Mio. USD | -0,60 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 29.04.2026 | 10-Q | 31.03.2026 | 29 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 29.10.2025 | 10-Q | 30.09.2025 | 29 Tage | SEC » |
| 30.07.2025 | 10-Q | 30.06.2025 | 30 Tage | SEC » |
| 30.04.2025 | 10-Q | 31.03.2025 | 30 Tage | SEC » |
| 19.02.2025 | 10-K | 31.12.2024 | 50 Tage | SEC » |
| 06.11.2024 | 10-Q | 30.09.2024 | 37 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 07.05.2024 | 10-Q | 31.03.2024 | 37 Tage | SEC » |
| 21.02.2024 | 10-K | 31.12.2023 | 52 Tage | SEC » |
| 02.11.2023 | 10-Q | 30.09.2023 | 33 Tage | SEC » |
| 09.08.2023 | 10-Q | 30.06.2023 | 40 Tage | SEC » |
| 03.05.2023 | 10-Q | 31.03.2023 | 33 Tage | SEC » |
| 22.02.2023 | 10-K | 31.12.2022 | 53 Tage | SEC » |
| 09.11.2022 | 10-Q | 30.09.2022 | 40 Tage | SEC » |
| 09.08.2022 | 10-Q | 30.06.2022 | 40 Tage | SEC » |
| 04.05.2022 | 10-Q | 31.03.2022 | 34 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 04.08.2021 | 10-Q | 30.06.2021 | 35 Tage | SEC » |
| 05.05.2021 | 10-Q | 31.03.2021 | 35 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 04.11.2020 | 10-Q | 30.09.2020 | 35 Tage | SEC » |
| 05.08.2020 | 10-Q | 30.06.2020 | 36 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 10.09.2024 | Kapitalerhöhung | – | SEC » |
| 09.09.2024 | Kapitalerhöhung | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | Form | |
|---|---|---|---|
| 23.04.2026 | HV-Einladung | DEFA14A | SEC » |
| 23.04.2026 | HV-Einladung | DEF 14A | SEC » |
| 25.04.2025 | HV-Einladung | DEFA14A | SEC » |
| 25.04.2025 | HV-Einladung | DEF 14A | SEC » |
| 25.04.2024 | HV-Einladung | DEFA14A | SEC » |
| 25.04.2024 | HV-Einladung | DEF 14A | SEC » |
| 20.04.2023 | HV-Einladung | DEFA14A | SEC » |
| 20.04.2023 | HV-Einladung | DEF 14A | SEC » |
| 20.04.2022 | HV-Einladung | DEFA14A | SEC » |
| 20.04.2022 | HV-Einladung | DEF 14A | SEC » |
| 20.05.2021 | HV-Einladung | DEFA14A | SEC » |
| 23.04.2021 | HV-Einladung | DEFA14A | SEC » |
| 23.04.2021 | HV-Einladung | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termine und Vergütung stehen im Dokument (SEC-Link).
Übernahmen & Fusionen (M&A)
M&A-relevante SEC-Filings der letzten sechs Jahre: Übernahmeangebote (Tender Offers), Fusionen (425/S-4), Aktienrückkauf-Angebote (Self-Tender) und Going-Private-Transaktionen. Geführt nach dem einreichenden Emittenten.
| Datum (US) | Kategorie | Form | Deal-Konditionen | SEC |
|---|---|---|---|---|
| 13.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
| 02.10.2020 | Übernahmeangebot | SC TO-T/A | – | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Deal-Konditionen aus dem Dokument extrahiert (Tender: SC TO-T/-I/SC 14D9; Fusion: 425/S-4 — Gegenpartei + Umtauschverhältnis), ohne Gewähr — Original siehe SEC-Link.
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (08.06.2026)
HOCH Abgang Schlüsselpersonen (08.06.2026)
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 08.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 09.03.2026 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 29.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.07.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 21.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 26.11.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 04.06.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.12.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 5.02 below. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 17.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 below is incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of… |
| 10.01.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 below is incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 10.07.2026 | Guidance-Update | 0,00 | 25 | Ionis Pharmaceuticals bestätigt ihre bisherige finanzielle Leitlinie für das Geschäftsjahr bis zum 31. Dezember 2026, wie sie am 29. April 2… 🔒 | SEC |
| 09.07.2026 | Quartalszahlen | -0,30 | 75 | Ionis Pharmaceuticals meldet, dass der Haupteffektziel von CARDIO-TTRansform, einem Phase-3-Studie zur eplontersen-Therapie bei Patienten mi… 🔒 | SEC |
| 24.06.2026 | Behördliche Maßnahme | 0,75 | 75 | Ionis Pharmaceuticals erhielt FDA-Zulassung für TRYNGOLZA® (olezarsen) zur Behandlung schwerer Hypertriglyzeridämie. Das Medikament wird mon… 🔒 | SEC |
| 12.06.2026 | Sonstiges | 0,65 | 45 | Ionis präsentierte auf der National Lipid Association Scientific Sessions positive neue Daten für olezarsen zur Behandlung schwerer Hypertri… 🔒 | SEC |
| 08.06.2026 | Personalwechsel | 0,20 | 35 | Ionis Pharmaceuticals ernannte Ludwig N. Hantson am 4. Juni 2026 zum Vorstandsmitglied. Die Ernennung wurde durch Pressemitteilung am 8. Jun… 🔒 | SEC |
| 28.05.2026 | Guidance-Update | 0,80 | 80 | GSK meldet positive Phase-3-Daten für das von Ionis lizenzierte Antisense-Therapie Bepirovirsen gegen chronische Hepatitis B. Ergebnisse aus… 🔒 | SEC |
| 29.04.2026 | Quartalszahlen | 0,00 | 55 | Ionis Pharmaceuticals gab Geschäftsergebnisse für Q1 2026 bekannt und veröffentlichte GAAP- und Non-GAAP-Ergebnisse. | SEC |
| 21.04.2026 | Sonstiges | 0,65 | 70 | Ionis Pharmaceuticals gab positive Ergebnisse aus einer pivotalen Studie zu Zilganersen bei Alexander-Krankheit bekannt, die auf der Jahrest… 🔒 | SEC |
| 09.03.2026 | Personalwechsel | -0,10 | 40 | B. Lynne Parshall tritt aus dem Board of Directors von Ionis Pharmaceuticals aus. | SEC |
| 25.02.2026 | Quartalszahlen | 0,00 | 65 | Ionis Pharmaceuticals kündigte Finanzierungsergebnisse für Q4 und Geschäftsjahr 2025 an, einschließlich GAAP- und Non-GAAP-Kennzahlen. | SEC |
| 12.01.2026 | Quartalszahlen | 0,45 | 50 | Ionis Pharmaceuticals gab vorläufige US-Nettoproduktverkäufe von TRYNGOLZA® für 2025 in Höhe von 105 Millionen Dollar bekannt. Die ungeprüft… 🔒 | SEC |
| 07.01.2026 | Sonstiges | 0,75 | 75 | GSK meldete positive Ergebnisse aus zwei Phase-3-Studien (B-Well 1 und B-Well 2) für Bepirovirsen zur Behandlung chronischer Hepatitis B. Di… 🔒 | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 42.698 | 80,69 | 3.445.302 |
| 2026-06-29 | 11.381 | 81,18 | 923.910 |
| 2026-06-25 | 1.864 | 76,52 | 142.633 |
| 2026-06-24 | 3 | 75,99 | 228 |
| 2026-06-23 | 7 | 75,89 | 531 |
| 2026-06-18 | 1.691 | 74,31 | 125.658 |
| 2026-06-17 | 25 | 73,09 | 1.827 |
| 2026-06-15 | 1.192 | 73,28 | 87.350 |
| 2026-06-12 | 7 | 73,82 | 517 |
| 2026-06-09 | 668 | 73,54 | 49.125 |
| 2026-06-08 | 15 | 74,48 | 1.117 |
| 2026-06-05 | 40.216 | 75,13 | 3.021.428 |
| 2026-06-04 | 333 | 73,82 | 24.582 |
| 2026-06-03 | 2.084 | 72,97 | 152.069 |
| 2026-05-29 | 199 | 77,33 | 15.389 |
| 2026-05-28 | 216 | 76,49 | 16.522 |
| 2026-05-21 | 7 | 75,06 | 525 |
| 2026-05-19 | 545 | 72,52 | 39.523 |
| 2026-05-18 | 848 | 74,23 | 62.947 |
| 2026-05-07 | 73 | 76,85 | 5.610 |
| 2026-05-04 | 7.917 | 75,28 | 595.992 |
| 2026-04-17 | 1 | 75,26 | 75 |
| 2026-04-13 | 1.892 | 75,17 | 142.222 |
| 2026-04-10 | 51 | 76,43 | 3.898 |
| 2026-04-07 | 110 | 74,33 | 8.176 |
| 2026-04-06 | 1.056 | 74,79 | 78.978 |
| 2026-04-02 | 61.032 | 75,13 | 4.585.334 |
| 2026-03-31 | 4.940 | 72,52 | 358.249 |
| 2026-03-26 | 1 | 72,70 | 73 |
| 2026-03-25 | 6.847 | 69,68 | 477.099 |
| 2026-03-23 | 5 | 70,99 | 355 |
| 2026-03-20 | 157 | 71,32 | 11.197 |
| 2026-03-19 | 30.432 | 71,67 | 2.181.061 |
| 2026-03-17 | 95 | 72,34 | 6.872 |
| 2026-03-13 | 755 | 72,34 | 54.617 |
| 2026-03-12 | 10.219 | 74,79 | 764.279 |
| 2026-03-11 | 1.337 | 75,66 | 101.157 |
| 2026-03-10 | 15.034 | 75,36 | 1.132.962 |
| 2026-03-04 | 71.539 | 78,66 | 5.627.258 |
| 2026-03-03 | 23.547 | 81,96 | 1.929.912 |
| 2026-02-25 | 34.535 | 85,45 | 2.951.016 |
| 2026-02-24 | 52.735 | 84,60 | 4.461.381 |
| 2026-02-23 | 19.581 | 83,15 | 1.628.160 |
| 2026-02-11 | 16.000 | 84,29 | 1.348.640 |
| 2026-02-06 | 86 | 83,48 | 7.179 |
| 2026-02-05 | 8.381 | 84,99 | 712.301 |
| 2026-02-03 | 456 | 83,07 | 37.880 |
| 2026-01-29 | 81 | 81,92 | 6.636 |
| 2026-01-23 | 3.066 | 81,79 | 250.768 |
| 2026-01-22 | 2.146 | 79,44 | 170.478 |
| 2026-01-21 | 2.546 | 77,53 | 197.391 |
| 2026-01-20 | 3.050 | 76,33 | 232.807 |